Glofitamab before or after stem cell transplant for relapsed lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests the drug glofitamab given before or after a stem cell transplant for patients whose B-cell lymphoma has returned or not improved. It aims to see if glofitamab can help make the transplant more effective or prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You have a type of B-cell lymphoma, like DLBCL or transformed low-grade lymphoma, that has come back or not responded to treatment.
- You have at least one tumor measurable on a CT scan.
- You are able to care for yourself (ECOG 0 or 1) and have a life expectancy of at least 6 months.
- You must not have active infections or serious heart, lung, or kidney problems.
- Women who can have children and men must use effective birth control during and for several months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called glofitamab before a stem cell transplant for people whose DLBCL has come back or not responded after at least two prior treatments. The goal is to see if this combination can help control the lymphoma before the transplant.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests a drug called glofitamab (a type of immunotherapy) given as a follow-up treatment after initial therapy for people with high-risk large B-cell lymphoma. The goal is to see if it helps keep the cancer from coming back.
This study is looking at how well the drug glofitamab works in people whose diffuse large B-cell lymphoma (a common type of lymphoma) didn't respond to, or came back quickly after, their first therapy. The goal is to learn how effective and safe glofitamab is in the real world when it is added to standard care.
This trial tests a drug called glofitamab, which helps your immune system attack lymphoma cells. It is for people with aggressive B-cell lymphoma that has grown after standard treatments. The study uses a biopsy to tailor the treatment during therapy.
This trial tests combining radiation therapy with a drug called glofitamab (a type of immunotherapy) for patients whose diffuse large B-cell lymphoma (DLBCL) has returned or stopped responding to previous treatments. The goal is to see if adding radiation to this newer drug helps control the cancer better.
Hear when a new Diffuse Large B Cell Lymphoma Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.